U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448441) titled 'Clinical Study of Trap-(FAPI)3 PET Imaging in the Diagnosis of Pulmonary Nodules' on Feb. 23.
Brief Summary: The excellent tumor-targeting efficacy of FAP has been confirmed by multiple clinical studies. The results unequivocally establish FAPI as a tumor-targeting ligand with significant potential, demonstrating important application prospects in translational oncology. However, its therapeutic effects remain under investigation. An ideal radiopharmaceutical for cancer treatment should possess outstanding targeting specificity and relatively prolonged tumor retention time. Previous studies have shown that radiolabeled FAPI variants...